Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
复制标题
DOI：
10.2217/fon-2021-0517
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
仍然迫切需要改进非小细胞肺癌的分期，因为即使在目前归类为“早期”的肿瘤完全切除后，由于手术时无法检测到的转移而导致的复发和死亡率仍然很高。基于14个基因的定量PCR表达谱已被广泛验证，以更好地识别手术切除后5年死亡率高风险的患者，而不是传统的分期-死亡率几乎总是由以前无法检测到的转移引起的。此外，前瞻性研究现在表明，当该检测用于指导早期非小细胞肺癌患者的辅助化疗决策时，无病生存率具有预测性益处。需要改进早期非小细胞肺癌的分期和治疗方式，因为许多患有“早期”疾病的患者在手术后癌症复发率很高。近年来，已经开发出一种专门的测试，可以根据肿瘤细胞表达的基因更好地表征肿瘤复发的风险。结合标准分期方法使用该测试，能够更好地识别手术后癌症复发风险高的患者。有证据表明，对手术后复发风险高的患者进行化疗可以降低复发率，提高患者的长期生存率。
There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as ‘early stage.’ A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging – mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients. There is a need for improvement in the way early-stage non-small-cell lung cancers are staged and treated because many patients with ‘early-stage’ disease suffer high rates of cancer recurrence after surgery. In recent years, a specialized test has been developed to allow better characterization of a tumor's risk of recurrence based on the genes being expressed by tumor cells. Use of this test, in conjunction with standard staging methods, is better able to identify patients at high risk of cancer recurrence after surgery. Evidence suggests that giving chemotherapy to patients at high risk of recurrence after surgery reduces recurrence rates and improves long-term patient survival.
登录
查看更多内容
影响因子：
4.6
作者：
Fang, DK;Zhang, DW;Zhang, DC
通讯作者：
Zhang, DC
影响因子：
82.9
作者：
Beer, DG;Kardia, SLR;Hanash, S
通讯作者：
Hanash, S
影响因子：
45.3
作者：
Arvold, Nils D.;Taghian, Alphonse G.;Harris, Jay R.
通讯作者：
Harris, Jay R.
影响因子：
9.6
作者：
Detterbeck, Frank C.;Boffa, Daniel J.;Tanoue, Lynn T.
通讯作者：
Tanoue, Lynn T.
影响因子：
2
作者：
Chambless, Lloyd E.;Cummiskey, Christopher P.;Cui, Gang
通讯作者：
Cui, Gang